A practical reference on Dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-27. Anything still debated is marked as such rather than presented as settled.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Appearance | white to off-white powder | Lyophilised solid form |
| Solubility | pH dependent; low near pI | Minimum close to pH 5.4 |
| Storage temperature | -20 C solid; 2-8 C solution | Protect from light |
| Isoelectric point | approx. pH 5.4 | Controls solubility minimum |
| Common analytical method | RP-HPLC with mass detection | Purity and identity checks |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
"APS user shares the "Israeli Nobel" for chemistry", from the Argonne National Laboratory Advanced Photon Source (APS), United States Department of Energy The Official Site of Louisa Gross Horwitz Prize Weizmann Institute of Science, Yonath-Site Talk by Ada Yonath at the Origins 2011 congress Ada E. Yonath on Nobelprize.org Ada Yonath at IMDb
Spondyloperipheral dysplasia is an autosomal dominant disorder of bone growth. The condition is characterized by flattened bones of the spine (platyspondyly) and unusually short fingers and toes (brachydactyly). Some affected individuals also have other skeletal abnormalities, short stature, nearsightedness (myopia), hearing loss, and mental retardation. Spondyloperipheral dysplasia is a subtype of collagenopathy, types II and XI.
Octodrine, also known as dimethylhexylamine (DMHA) and sold under the brand name Vaporpac among others, is a sympathomimetic and stimulant medication that was formerly used in the treatment of hypotension (low blood pressure). It has been studied in a dozen animal studies from the 1940s through the 1970s. These studies found that octodrine can increase blood pressure and cardiac output in animals. The drug was previously approved for use by the Food and Drug Administration (FDA) as an inhalant (i.e., Vaporpac and Tickle Tackle Inhaler) and in Germany as an oral medication as part of a multi-component medication (i.e., Ambredin and Ordinal), but is no longer available. DMHA has also been found as an adulterant in preworkout products and is also sold online as a designer drug. The presence of a reductive amination byproduct in seized samples confirms the drug is fully synthetic in origin. In the United States, the FDA considers DMHA to be an unsafe ingredient in dietary supplements. In 2019, the FDA issued nine warning letters to US manufacturers of dietary supplements containing DMHA as an unsafe food additive, deeming such products to be adulterated and illegal for marketing.
Sources: en.wikipedia.org
Plant protein can meet protein requirements when a variety of plant foods is consumed and energy needs are met. Research indicates that an assortment of plant foods eaten over the course of a day can provide all essential amino acids and ensure adequate nitrogen retention and use in healthy adults, thus, complementary proteins do not need to be consumed at the same meal. The American Heart Association now states:
=== Leadership rival === Although (or perhaps because) many of Heseltine's policy positions were not far removed from those of Labour, which was shifting to the right under Kinnock, he kept up his Conservative credentials at this time. In alliance with Norman Tebbit he persuaded ministers to abolish the Inner London Education Authority. He also supported the government's planned market-led reforms to the NHS and water privatisation in 1989. He also spoke out frequently on defence matters, supported the government's ban on Spycatcher, the new Official Secrets Act 1989 and called for an independent Bank of England, although perhaps as a stepping stone to the setting up of a European Central Bank. One of the reasons which Thatcher gave to close confidants for not retiring on her tenth anniversary as Prime Minister (May 1989) was worry that Heseltine would defeat Geoffrey Howe in any subsequent leadership election. Opinion polls showed that Heseltine would boost Conservative support by 13 percentage points – enough to overtake Labour. Sir Anthony Meyer wanted to see Heseltine as leader and only went ahead with his December 1989 leadership challenge to Thatcher on being assured by Keith Hampson that it would not damage Heseltine's chances; in the event Heseltine apparently walked up and down the corridor outside the voting booth making clear that he was abstaining.
=== Do–Du === George H. Dodd (c. 1942–2020). British biochemist who studied perfumes and pheromones. Edward Adelbert Doisy (1893–1986). American biochemist at St Louis University, known for discovering vitamin K. Nobel Prize in Physiology or Medicine (1943). Ford Doolittle (b. 1942). American biochemist at Dalhousie University, known for contributions to the study of cyanobacteria and of biochemical evolution in general. Member Natl. Acad. Sci. USA. Jonathan Dordick (b. 1959). American biochemical engineer at Rensselaer Polytechnic Institute, known for development of enzyme catalysis under extreme conditions. Ralph Dorfman (1911–1985). American biochemist at Stanford, known for treatments for cancer and rheumatoid arthritis Jennifer Doudna (b. 1964). American biochemist at UC Berkeley, known for CRISPR-mediated genome editing. Member Natl. Acad. Sci. USA. Nobel Prize in Chemistry, 2020. Alexander Dounce (1909–1997). American protein chemist at the University of Rochester, active in early work on the genetic code, one of the first to suggest that it was triplet-based. Gideon Dreyfuss (PhD 1978). American biochemist and biophysicist at the University of Pennsylvania, concerned with the function and biogenesis of non-coding RNA and the proteins that interact with RNA. Member Natl. Acad. Sci. USA. Jack Cecil Drummond FRS (1891–1952). British biochemist at University College London, known for the isolation of Vitamin A, and wartime advisor on nutrition. Murdered in France, with his wife and daughter. Vincent du Vigneaud (1901–1978).
Sources: en.wikipedia.org
On 16 March, Pakistan said that its forces launched multiple airstrikes against Taliban military installations in Kabul and Nangarhar, and claimed that it destroyed ammo storages and "technical support infrastructure". Taliban claimed that Pakistani strikes on Khost province killed four civilians and wounded nine, and destroyed civilian infrastructure in Kunar and Paktika province with 43 rounds being fired into Shkin district. A militant attack on a police post in Bannu District was repulsed by police forces. Following the strikes, Afghanistan claimed that a Pakistani airstrike struck the Omid Addiction Treatment Hospital in Kabul, reportedly killing over 200 people, mostly drug addicts undergoing treatment at the drug rehabilitation facility. Pakistan denied the claims and said that it had only targeted Taliban military installations. While the health ministry spokesperson maintained that there were "more than 200 martyrs and more than 200 injured," deputy government spokesperson Hamdullah Fitrat claimed death toll was at least "double" that, with 250 wounded. Zabihullah Mujahid declared it a "crime against humanity". On 17 March, five Pakistani soldiers were killed and three wounded in a skirmish at Ghulam Khan border crossing in North Waziristan District. A militant attack in Badaber injured two policemen. On 18 March, Pakistani missile strikes in Asadabad wounded six civilians. According to Taliban, Pakistan conducted 63 missile strikes on Nari District, 33 on Manogai, 13 on Sarkani, six on Shultan and six on Asadabad.
The G-spot is analogous to the base of the penis and has additionally been theorized, with the sentiment from researcher Amichai Kilchevsky that because female fetal development is the "default" state in the absence of substantial exposure to male hormones and therefore the penis is essentially a clitoris enlarged by such hormones, there is no evolutionary reason why females would have an entity in addition to the clitoris that can produce orgasms. The general difficulty of achieving orgasms vaginally, which is a predicament that is likely due to nature easing the process of childbearing by drastically reducing the number of vaginal nerve endings, challenge arguments that vaginal orgasms help encourage sexual intercourse to facilitate reproduction. Supporting a distinct G-spot, however, is a study by Rutgers University, published in 2011, which was the first to map the female genitals onto the sensory portion of the brain; the scans indicated that the brain registered distinct feelings between stimulating the clitoris, the cervix and the vaginal wall – where the G-spot is reported to be – when several women stimulated themselves in a functional magnetic resonance machine. Barry Komisaruk, head of the research findings, stated that he feels that "the bulk of the evidence shows that the G-spot is not a particular thing" and that it is "a region, it's a convergence of many different structures".
=== Contraction === Neuromuscular junctions are the focal point where a motor neuron attaches to a muscle. Acetylcholine, (a neurotransmitter used in skeletal muscle contraction) is released from the axon terminal of the nerve cell when an action potential reaches the microscopic junction called a synapse. A group of chemical messengers across the synapse and stimulate the formation of electrical changes, which are produced in the muscle cell when the acetylcholine binds to receptors on its surface. Calcium is released from its storage area in the cell's sarcoplasmic reticulum. An impulse from a nerve cell causes calcium release and brings about a single, short muscle contraction called a muscle twitch. If there is a problem at the neuromuscular junction, a very prolonged contraction may occur, such as the muscle contractions that result from tetanus. Also, a loss of function at the junction can produce paralysis. Skeletal muscles are organized into hundreds of motor units, each of which involves a motor neuron, attached by a series of thin finger-like structures called axon terminals. These attach to and control discrete bundles of muscle fibers. A coordinated and fine-tuned response to a specific circumstance will involve controlling the precise number of motor units used. While individual muscle units' contract as a unit, the entire muscle can contract on a predetermined basis due to the structure of the motor unit. Motor unit coordination, balance, and control frequently come under the direction of the cerebellum of the brain.
After injection, inhalation, or ingestion, the first symptoms to appear are generalized muscle spasms. They appear very quickly after inhalation or injection – within as few as five minutes – and take somewhat longer to manifest after ingestion, typically approximately 15 minutes. With a very high dose, the onset of respiratory failure and brain death can occur in 15 to 30 minutes. If a lower dose is ingested, other symptoms begin to develop, including seizures, cramping, stiffness, hypervigilance, and agitation. Seizures caused by strychnine poisoning can start as early as 15 minutes after exposure and last 12–24 hours. They are often triggered by sights, sounds, or touch and can cause other adverse symptoms, including hyperthermia, rhabdomyolysis, myoglobinuric kidney failure, metabolic acidosis, and respiratory acidosis. During seizures, mydriasis (abnormal dilation), exophthalmos (protrusion of the eyes), and nystagmus (involuntary eye movements) may occur. As strychnine poisoning progresses, tachycardia (rapid heart beat), hypertension (high blood pressure), tachypnea (rapid breathing), cyanosis (blue discoloration), diaphoresis (sweating), water-electrolyte imbalance, leukocytosis (high number of white blood cells), trismus (lockjaw), risus sardonicus (spasm of the facial muscles), and opisthotonus (dramatic spasm of the back muscles, causing arching of the back and neck) can occur. In rare cases, the affected person may experience nausea or vomiting.
Sources: en.wikipedia.org
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.
Mass spectrometry, usually electrospray ionisation coupled to liquid chromatography, gives an observed mass for comparison with the theoretical value. Peptide mapping after digestion provides complementary sequence-level confirmation.
Short exposure during weighing and handling is generally tolerated, but prolonged storage above refrigerated conditions raises the risk of deamidation, oxidation, and aggregation. The rate depends on pH, buffer composition, and concentration.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.